Over expression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]αSyn transgenic mice

Human Molecular Genetics

Volumn 23, Issue 15, 2014, Pages 3975-3989

  Diepenbroek, Meike ^a   Casadei, Nicolas ^a   Esmer, Hakan ^a   Saido, Takaomi C ^b   Takano, Jiro ^b   Kahle, Philipp J ^c   Nixon, Ralph A ^d   Rao, Mala V ^d   Melki, Ronald ^e   Pieri, Laura ^e   Helling, Stefan ^f   Marcus, Katrin ^f   Krueger, Rejko ^c   Masliah, Eliezer ^g,h   Riess, Olaf ^a   Nuber, Silke ^a,h  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^e LABORATOIRE D ENZYMOLOGIE ET BIOCHIMIE STRUCTURALES   (France)

^f RUHR UNIVERSITY BOCHUM   (Germany)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; CALPAIN; CALPAIN 1; CALPASTATIN; CALCIUM BINDING PROTEIN; CAPN1 PROTEIN, MOUSE; PROTEIN AGGREGATE; SNCA PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTOSIS; CELL AGGREGATION; CELL INCLUSION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PROCESSING; SYNAPSE; TRANSGENIC MOUSE; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; LEWY BODY; METABOLISM; NERVE CELL; PATHOLOGY; PROTEIN DEGRADATION; PROTEINOSIS; SIGNAL TRANSDUCTION;

ALPHA-SYNUCLEIN; ANIMALS; CALCIUM-BINDING PROTEINS; CALPAIN; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HUMANS; LEWY BODIES; MICE; MICE, TRANSGENIC; NEURONS; PARKINSON DISEASE; PROTEIN AGGREGATES; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEOLYSIS; SIGNAL TRANSDUCTION; SYNAPSES;

EID: 84903946788     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddu112     Document Type: Article

References (73)

1. Takeda, A., Mallory, M., Sundsmo, M., Honer, W., Hansen, L. and Masliah, E. (1998) Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. Am. J. Pathol., 152, 367-372.
2. Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R. and Goedert, M. (1997) Alpha-synuclein in Lewy bodies. Nature, 388, 839-840.
3. Dufty, B.M., Warner, L.R., Hou, S.T., Jiang, S.X., Gomez-Isla, T., Leenhouts, K.M., Oxford, J.T., Feany, M.B., Masliah, E. and Rohn, T.T. (2007) Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation. Am. J. Pathol., 170, 1725-1738.
4. Braak, H., Del Tredici, K., Rüb, U., de Vos, R.A.I., Jansen Steur, E.N.H. and Braak, E. (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging, 24, 197-211.
5. Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H. and Del Tredici, K. (2004) Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res., 318, 121-134.
6. Irvine, G.B., El-Agnaf, O.M., Shankar, G.M. and Walsh, D.M. (2008) Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases. Mol. Med., 14, 451-464.
7. Conway, K.A., Lee, S.J., Rochet, J.C., Ding, T.T., Williamson, R.E. and Lansbury, P.T. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl Acad. Sci. USA, 97, 571-576.
8. Uversky, V.N., Li, J. and Fink, a.L. (2001) Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J. Biol. Chem., 276, 10737-10744.
9. Zhu, M. and Fink, A.L. (2003) Lipid binding inhibits alpha-synuclein fibril formation. J. Biol. Chem., 278, 16873-16877.
10. Zhu, M., Li, J. and Fink, A.L. (2003) The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation. J. Biol. Chem., 278, 40186-40197.
11. Iwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., de Silva, H.A., Kittel, A. and Saitoh, T. (1995) The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron, 14, 467-475.
12. Hong, D.-P., Xiong, W., Chang, J.-Y. and Jiang, C. (2011) The role of the C-terminus of human a-synuclein: intra-disulfide bonds between the C-terminus and other regions stabilize non-fibrillar monomeric isomers. FEBS Lett., 585, 561-566.
13. Bertoncini, C.W., Jung, Y.-S., Fernandez, C.O., Hoyer, W., Griesinger, C., Jovin, T.M. and Zweckstetter, M. (2005) Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. Proc. Natl Acad. Sci. USA, 102, 1430-1435.
14. Lowe, R., Pountney, D.L., Jensen, P.H., Gai, W.P. and Voelcker, N.H. (2004) Calcium(II) selectively induces alpha-synuclein annular oligomers via interaction with the C-terminal domain. Protein Sci., 13, 3245-3252.
15. Li, W., West, N., Colla, E., Pletnikova, O., Troncoso, J.C., Marsh, L., Dawson, T.M., Jakala, P., Hartmann, T., Price, D.L. et al. (2005) Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc. Natl Acad. Sci. USA, 102, 2162-2167.
16. Liu, C.-W., Giasson, B.I., Lewis, K.A., Lee, V.M., Demartino, G.N. and Thomas, P.J. (2005) A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. J. Biol. Chem., 280, 22670-22678.
17. Wakamatsu, M., Ishii, A., Iwata, S., Sakagami, J., Ukai, Y., Ono, M., Kanbe, D., Muramatsu, S., Kobayashi, K., Iwatsubo, T. et al. (2008) Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice. Neurobiol. Aging, 29, 574-585.
18. Ulusoy, A., Febbraro, F., Jensen, P.H., Kirik, D. and Romero-Ramos, M. (2010) Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology. Eur. J. Neurosci., 32, 409-422.
19. Tofaris, G.K., Garcia Reitböck, P., Humby,T., Lambourne, S.L., O'Connell, M., Ghetti, B., Gossage, H., Emson, P.C., Wilkinson, L.S., Goedert, M. et al. (2006) Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders. J. Neurosci., 26, 3942-3950.
20. Kim, K.S., Choi, Y.R., Park, J.-Y., Lee, J.-H., Kim, D.K., Lee, S.-J., Paik, S.R., Jou, I. and Park, S.M. (2012) Proteolytic cleavage of extracellular a-synuclein by plasmin: implications for Parkinson disease. J. Biol. Chem., 287, 24862-24872.
21. Sung, J.Y., Park, S.M., Lee, C.-H., Um, J.W., Lee, H.J., Kim, J., Oh, Y.J., Lee, S.-T., Paik, S.R. and Chung, K.C. (2005) Proteolytic cleavage of extracellular secreted {alpha}-synuclein via matrix metalloproteinases. J. Biol. Chem., 280, 25216-25224.
22. Sevlever, D., Jiang, P. and Yen, S.-H.C. (2008) Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species. Biochemistry, 47, 9678-9687.
23. Ogawa, K., Yamada, T., Tsujioka, Y., Taguchi, J., Takahashi, M., Tsuboi, Y., Fujino, Y., Nakajima, M., Yamamoto, T., Akatsu, H. et al. (2000) Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer's disease and Parkinson's disease. Psychiatry Clin. Neurosci., 54, 419-426.
24. Iwata, A., Maruyama, M., Akagi, T., Hashikawa, T., Kanazawa, I., Tsuji, S. and Nukina, N. (2003) Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies. Hum. Mol. Genet., 12, 2625-2635.
25. Oueslati, A., Fournier, M. and Lashuel, H.A. (2010) Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies. Prog. Brain Res. 183, 115-145.
26. Vosler, P.S., Brennan, C.S. and Chen, J. (2008) Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. Mol. Neurobiol., 38, 78-100.
27. Liu, J., Liu, M.C. and Wang, K.K.W. (2008) Calpain in the CNS: from synaptic function to neurotoxicity. Sci. Signal., 1, re1.
28. Hübener, J., Weber, J.J., Richter, C., Honold, L., Weiss, A., Murad, F., Breuer, P., Wüllner, U., Bellstedt, P., Paquet-Durand, F. et al. (2012) Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3). Hum. Mol. Genet. doi:10.1093/hmg/ dds449.
29. Liang, B., Duan, B.-Y., Zhou, X.-P., Gong, J.-X. and Luo, Z.-G. (2010) Calpain activation promotes BACE1 expression, amyloid precursor protein processing, and amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J. Biol. Chem., 285, 27737-27744.
30. Rao, M.V., Mohan, P.S., Peterhoff, C.M., Yang, D.-S., Schmidt, S.D., Stavrides, P.H., Campbell, J., Chen, Y., Jiang, Y., Paskevich, P.a. et al. (2008) Marked calpastatin (CAST) depletion in Alzheimer's disease accelerates cytoskeleton disruption and neurodegeneration: neuroprotection by CAST overexpression. J. Neurosci., 28, 12241-12254.
31. Wu, H.-Y. and Lynch, D.R. (2006) Calpain and synaptic function. Mol. Neurobiol., 33, 215-236.
32. Mishizen-Eberz, A.J., Norris, E.H., Giasson, B.I., Hodara, R., Ischiropoulos, H., Lee, V.M.-Y., Trojanowski, J.Q. and Lynch, D.R. (2005) Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein. Biochemistry, 44, 7818-7829.
33. Mishizen-Eberz, A.J., Guttmann, R.P., Giasson, B.I., Day, G.A., Hodara, R., Ischiropoulos, H., Lee, V.M.-Y., Trojanowski, J.Q. and Lynch, D.R. (2003) Distinct cleavage patterns of normal and pathologic forms of a-synuclein by calpain I in vitro. J. Neurochem., 86, 836-847.
34. Crocker, S.J., Smith, P.D., Jackson-Lewis, V., Lamba, W.R., Hayley, S.P., Grimm, E., Callaghan, S.M., Slack, R.S., Melloni, E., Przedborski, S. et al. (2003) Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease. J. Neurosci., 23, 4081-4091.
35. Takano, J., Tomioka, M., Tsubuki, S., Higuchi, M., Iwata, N., Itohara, S., Maki, M. and Saido, T.C. (2005) Calpain mediates excitotoxic DNA fragmentation via mitochondrial pathways in adult brains: evidence from calpastatin mutant mice. J. Biol. Chem., 280, 16175-16184.
36. Freichel, C., Neumann, M., Ballard, T.,Müller, V., Woolley, M., Ozmen, L., Borroni, E., Kretzschmar, H.A., Haass, C., Spooren, W. et al. (2007) Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice. Neurobiol. Aging, 28, 1421-1435.
37. Kahle, P.J., Neumann, M., Ozmen, L., Muller, V., Jacobsen, H., Schindzielorz, A., Okochi, M., Leimer, U., van Der Putten, H., Probst, A. et al. (2000) Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain. J. Neurosci., 20, 6365-6373.
38. Neumann, M., Kahle, P.J., Giasson, B.I., Ozmen, L., Borroni, E., Spooren, W.,Mü ller, V., Odoy, S., Fujiwara, H., Hasegawa,M.et al. (2002) Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J. Clin. Invest., 110, 1429-1439.
39. Conway, K.a., Harper, J.D. and Lansbury, P.T. (1998) Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med., 4, 1318-1320.
40. el-Agnaf, O.M.A. and Irvine, G.B. (2002) Aggregation and neurotoxicity of alpha-synuclein and related peptides. Biochem. Soc. Trans., 30, 559-565.
41. Volles, M.J. and Lansbury, P.T. (2003) Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry, 42, 7871-7878.
42. Conway,K.A., Harper, J.D. and Lansbury, P.T. (2000) Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry, 39, 2552-2563.
43. Seidel, K., Schöls, L., Nuber, S., Petrasch-Parwez, E., Gierga, K., Wszolek, Z., Dickson, D., Gai, W.P., Bornemann, A., Riess, O. et al. (2010) First appraisal of brain pathology owing to A30P mutant alpha-synuclein. Ann. Neurol., 67, 684-689.
44. Langston, J.W., Sastry, S., Chan, P., Forno, L.S., Bolin, L.M. and Di Monte, D.A. (1998) Novel alpha-synuclein-immunoreactive proteins in brain samples from the Contursi kindred, Parkinson's, and Alzheimer's disease. Exp. Neurol., 154, 684-690.
45. Jensen, P.H., Nielsen, M.S., Jakes, R., Dotti, C.G. and Goedert, M. (1998) Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J. Biol. Chem., 273, 26292-26294.
46. Games, D., Seubert, P., Rockenstein, E., Patrick, C., Trejo, M., Ubhi, K., Ettle, B., Ghassemiam, M., Barbour, R., Schenk, D. et al. (2013)Axonopathy in an a-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated a-synuclein. Am. J. Pathol., 182, 940-953.
47. Nuber, S., Tadros, D., Fields, J., Overk, C.R., Ettle, B., Kosberg, K., Mante, M., Rockenstein, E., Trejo, M. and Masliah, E. (2014) Environmental neurotoxic challenge of conditional alpha-synuclein transgenic mice predicts a dopaminergic olfactory-striatal interplay in early PD. Acta Neuropathol. doi:10.1007/s00401-014-1255-5.
48. Burré, J., Sharma, M. and Südhof, T.C. (2012) Systematic mutagenesis of a-synuclein reveals distinct sequence requirements for physiological and pathological activities. J. Neurosci., 32, 15227-15242.
49. Nixon, R.A., Saito, K.I., Grynspan, F., Griffin, W.R., Katayama, S., Honda, T., Mohan, P.S., Shea, T.B. and Beermann, M. (1994) Calcium-activated neutral proteinase (calpain) system in aging and Alzheimer's disease. Ann. N. Y. Acad. Sci., 747, 77-91.
50. Gafni, J. and Ellerby, L.M. (2002) Calpain activation in Huntington's disease. J. Neurosci., 22, 4842-4849.
51. Daher, J.P.L., Ying, M., Banerjee, R., McDonald, R.S., Hahn, M.D., Yang, L., Flint Beal, M., Thomas, B., Dawson, V.L., Dawson, T.M. et al. (2009) Conditional transgenic mice expressing C-terminally truncated human alpha-synuclein (alphaSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons. Mol. Neurodegener., 4, 34.
52. Goll, D.E., Thompson, V.F., Li, H., Wei, W.and Cong, J. (2003) The calpain system. Physiol. Rev., 83, 731-801.
53. Czogalla, a. and Sikorski, a.F. (2005) Spectrin and calpain: a "target" and a "sniper" in the pathology of neuronal cells. Cell. Mol. Life Sci., 62, 1913-1924.
54. Schmid, A.W., Fauvet, B., Moniatte, M. and Lashuel, H.A. (2013) Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson's disease and other synucleinopathies. Mol. Cell. Proteomics. doi:10.1074/mcp.R113.032730.
55. Masliah, E., Rockenstein, E., Mante, M., Crews, L., Spencer, B., Adame, A., Patrick, C., Trejo, M., Ubhi, K., Rohn, T.T. et al. (2011) Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS ONE, 6, e19338.
56. Danzer, K.M., Haasen, D., Karow, A.R., Moussaud, S., Habeck, M., Giese, A., Kretzschmar, H., Hengerer, B. and Kostka, M. (2007) Different species of alpha-synuclein oligomers induce calcium influx and seeding. J. Neurosci., 27, 9220-9232.
57. Pieri, L., Madiona, K., Bousset, L. and Melki, R. (2012) Fibrillara-synuclein and huntingtin exon 1 assemblies are toxic to the cells. Biophys. J., 102, 2894-2905.
58. Stefanis, L. (2012) A-Synuclein in Parkinson's disease. Cold Spring Harb. Perspect. Med., 2, a009399.
59. Nemani, V.M., Lu, W., Berge, V., Nakamura, K., Onoa, B., Lee, M.K., Chaudhry, F.A., Nicoll, R.A. and Edwards, R.H. (2010) Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron, 65, 66-79.
60. Schulz-Schaeffer, W.J. (2010) The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol., 120, 131-143.
61. Lim, Y., Kehm, V.M., Lee, E.B., Soper, J.H., Li, C., Trojanowski, J.Q. and Lee, V.M.-Y. (2011) a-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies. J. Neurosci., 31, 10076-10087.
62. Nuber, S., Harmuth, F., Kohl, Z., Adame, A., Trejo, M., Schönig, K., Zimmermann, F., Bauer, C., Casadei, N., Giel, C. et al. (2013) Aprogressive dopaminergic phenotype associated with neurotoxic conversion of a-synuclein in BAC-transgenic rats. Brain, 136, 412-432.
63. Du, S., Rubin, A., Klepper, S., Barrett, C., Kim, Y.C., Rhim, H.W., Lee, E.B., Park, C.W., Markelonis, G.J. and Oh, T.H. (1999) Calcium influx and activation of calpain I mediate acute reactive gliosis in injured spinal cord. Exp. Neurol., 157, 96-105.
64. Gray, B.C., Skipp, P., O'Connor, V.M. and Perry, V.H. (2006) Increased expression of glial fibrillary acidic protein fragments and mu-calpain activation within the hippocampus of prion-infected mice. Biochem. Soc. Trans., 34, 51-54.
65. Easley-Neal, C., Fierro, J., Buchanan, J. and Washbourne, P. (2013) Late recruitment of synapsin to nascent synapses is regulated by Cdk5. Cell Rep., 3, 1199-1212.
66. Sato, K., Minegishi, S., Takano, J., Plattner, F., Saito, T., Asada, A., Kawahara, H., Iwata, N., Saido, T.C. and Hisanaga, S. (2011) Calpastatin, an endogenous calpain-inhibitor protein, regulates the cleavage of the Cdk5 activator p35 to p25. J. Neurochem., 117, 504-515.
67. Ghee, M., Melki, R., Michot, N. and Mallet, J. (2005) PA700, the regulatory complex of the 26S proteasome, interferes with alpha-synuclein assembly. FEBS J., 272, 4023-4033.
68. Schuck, P. (2000) Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling. Biophys. J., 78, 1606-1619.
69. Tofaris, G.K., Razzaq, A., Ghetti, B., Lilley, K.S. and Spillantini, M.G. (2003) Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J. Biol. Chem., 278, 44405-44411.
70. Casadei, N., Pöhler, A.-M., Tomás-Zapico, C., Torres-Peraza, J., Schwedhelm, I., Witz, A., Zamolo, I., De Heer, R., Spruijt, B., Noldus, L.P.J.J. et al. (2013) Overexpression of synphilin-1 promotes clearance of soluble and misfolded alpha-synuclein without restoring the motor phenotype in aged A30P transgenic mice. Hum. Mol. Genet. doi:10.1093/ hmg/ddt467.
71. Jungblut, P.R. and Seifert, R. (1990) Analysis by high-resolution two-dimensional electrophoresis of differentiation-dependent alterations in cytosolic protein pattern of HL-60 leukemic cells. J. Biochem. Biophys. Methods, 21, 47-58.
72. Tanji, K., Mori, F., Mimura, J., Itoh, K., Kakita, A., Takahashi, H. and Wakabayashi, K. (2010) Proteinase K-resistant alpha-synuclein is deposited in presynapses in human Lewy body disease and A53T alpha-synuclein transgenic mice. Acta Neuropathol., 120, 145-154.
73. Nuber, S., Petrasch-Parwez, E., Winner, B., Winkler, J., von Hörsten, S., Schmidt, T., Boy, J., Kuhn, M., Nguyen, H.P., Teismann, P. et al. (2008) Neurodegeneration and motor dysfunction in a conditional model of Parkinson's disease. J. Neurosci., 28, 2471-2484.